Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.62 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | CDC42 | P60953 | 1/20 | 0.62 |
| ▸ | RAC1 | P63000 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15889896 | 0.84 | TDP1 (0.67) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL19719468 | 0.83 | PTGS2 (0.60) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL218780 | 0.82 | PTGS2 (0.58) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL29508603 | 0.82 | TDP1 (0.77) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL505819 | 0.82 | TDP1 (0.77) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL505799 | 0.82 | TDP1 (0.77) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL505811 | 0.82 | TDP1 (0.77) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL29403959 | 0.82 | TDP1 (0.77) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL9551659 | 0.82 | TDP1 (0.77) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL8754690 | 0.82 | TDP1 (0.77) | TDP1L3MBTL1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998932-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | Parsons, C. Lowell (US) | 2022-05-25 | — | — | EP | claimed |
| WO-2021011566-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | PARSONS C LOWELL (US) | 2021-01-21 | — | — | WO | claimed |
| EP-3609483-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | Urigen Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| WO-2018191412-A9 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2019-05-31 | — | — | WO | claimed |
| WO-2018191412-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | claimed |
| EP-2494967-A1 | Novel composition for treating metabolic syndrome | IPINTL, LLC (US) | 2012-09-05 | — | — | EP | claimed |
| WO-2012112690-A2 | TARGETING OF THERAPEUTIC DRUGS AND DIAGNOSTIC AGENTS EMPLOYING COLLAGEN BINDING DOMAINS | FABIUS BIOTECHNOLOGY (US) | 2012-08-23 | — | — | WO | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| JP-2006516202-A | — | — | 2006-06-29 | — | — | JP | claimed |
| CN-1732022-A | Silk stent grafts | ANGIOTECH INTERNAT GMBH (CH) | 2006-02-08 | — | — | CN | claimed |
| EP-1581270-A2 | SILK-CONTAINING STENT GRAFT | ANGIOTECH INTERNATIONAL AG (CH) | 2005-10-05 | — | — | EP | claimed |
| US-20040199241-A1 | Silk stent grafts | ANGIOTECH INTERNATIONAL AG (CH) | 2004-10-07 | — | — | US | claimed |
| WO-2004060424-A2 | SILK-CONTAINING STENT GRAFT | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | claimed |
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | VANELTIX PHARMA, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| EP-3523274-B1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | ORBUS THERAPEUTICS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-20040199241-A1 | Silk stent grafts | ANGIOTECH INTERNATIONAL AG (CH) | 2004-10-07 | — | — | US | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060424-A2 | SILK-CONTAINING STENT GRAFT | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004050639-A2 | 5-NITROSO-6-PIPERAZINYL-PYRIMIDINE DERIVATIVES FOR TREATING ISCHEMIA | EPCELLON, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | TDP1 201/4885L3MBTL1 462/4885TSHR 4307/4885 |
| US-12491207-B2 | Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability | OGFR, ALOX5, PTGS1 | TDP1 3401/4885L3MBTL1 3214/4885TSHR 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.